Skip to main content

Korean firm plans CDMO business

Hanmi Fine Chemical, an API manufacturing subsidiary of Hanmi Pharmaceutical, has announced plans for a new business offering what it calls ‘high-tech CDMO’ services. It will spend €7.4 million to build facilities for them and expects to form partnerships with more companies in 2H 2022, in addition to the ten it already has.

Subscribe to Hanmi Pharmaceutical